United States securities and exchange commission logo




                                                                                
                          April 29, 2024

       Bas van der Baan
       Chief Executive Officer
       Lixte Biotechnology Holdings, Inc.
       680 East Colorado Boulevard, Suite 180
       Pasadena, California 91101

                                                        Re: Lixte Biotechnology 
Holdings, Inc.
                                                            Registration 
Statement on Form S-3
                                                            Filed April 23, 
2024
                                                            File No. 333-278874

       Dear Bas van der Baan:

              This is to advise you that we have not reviewed and will not 
review your registration
       statement.

               Please refer to Rules 460 and 461 regarding requests for 
acceleration. We remind you
       that the company and its management are responsible for the accuracy and 
adequacy of their
       disclosures, notwithstanding any review, comments, action or absence of 
action by the staff.

                                                        Please contact Tim 
Buchmiller at 202-551-3635 with any questions.



                                                                                
                          Sincerely,

                                                                                
                          Division of Corporation Finance
                                                                                
                          Office of Life Sciences
       cc:                                              David Ficksman, Esq.